MARY ANNE CARDENAS: Open Payments
NPI 1073223368 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,212 in 94 payments from 19 companies in 2025. Trend: 2023 $1,149 · 2024 $3,541 · 2025 $2,212
Food & beverage: $2,212
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 47 | $1,133 |
| Neurocrine BioSciences, Inc. | 6 | $219 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $150 |
| ARGENX US, INC. | 9 | $137 |
| UCB, Inc. | 4 | $130 |
| Teva Pharmaceuticals USA, Inc. | 3 | $66 |
| Janssen Biotech, Inc. | 3 | $56 |
| Genentech USA, Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| GENZYME CORPORATION | 1 | $32 |
Products named: BOTOX, QULIPTA, UBRELVY, INGREZZA, HYQVIA, Rystiggo, VYVGART HYTRULO, AUSTEDO XR.
Industry payments across NV — which companies pay providers there.
